Recruiting

Genio® System

Sponsor:

Nyxoah Inc.

Code:

NCT07331285

Conditions

Obstructive Sleep Apnea

Eligibility Criteria

Sex: All

Age: 22+

Healthy Volunteers: Not accepted

Interventions

This is a single arm study, all consented and eligible subjects will be implanted with the Genio® System 2.1

Study Details

Brief summary:

The objective of the BREATHE study is to demonstrate the continued safety and effectiveness of the Genio® System in treating subjects diagnosed with moderate to severe obstructive sleep apnea (OSA) who are intolerant to or failed/refused PAP treatments.

Conditions

Obstructive Sleep Apnea

Study ID

NCT07331285

Start date

Jun, 2026

Status verified date

Jun, 2026

Completion date

Oct, 2032

Anticipated

Primary completion date

Oct, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 22+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Have an apnea-hypopnea index (AHI) greater than or equal to 15 and less than or equal to 65, measured on a full-night PSG performed no earlier than 2 years prior to enrollment (AHI4 and ODI4 available).
2. Be adults 22 years of age and older.
3. Have been confirmed to have failed, not tolerated, or be ineligible to be treated with current standard of care treatments for moderate to severe OSA.
4. Have pursued insurance pre-authorization for Genio® Therapy, recognizing that pre-authorization does not ensure payment, or demonstrate willingness to assume any out-of-pocket costs. The sponsor will not be responsible for treatment-related charges.
5. Agree to participate in the study and voluntarily sign and date an informed consent form.
6. Be willing and capable of complying with all study requirements, including specific lifestyle considerations, performing all follow-up visits, evaluation procedures and questionnaires for the whole duration of the trial.
7. Have a result of a Drug- Induced Sleep Endoscopy (DISE), no earlier than 2 years prior to enrollment.

Exclusion Criteria:

1. Combined central and mixed apnea-hypopnea index (AHI) greater than or equal to 25% of the total AHI.
2. Any functional or structural problem, medical illness or condition that would prevent or interfere with implantation, activation or continued use of the Genio® Therapy.
3. Have an implantable device which may be susceptible to unintended interaction with the Genio® System 2.1.
4. Women who are pregnant, planning to become pregnant or breastfeeding.
5. Any condition or procedure that has compromised neurological control of the upper airway.
6. Be part of the populations for which the safety and effectiveness of the Genio® System 2.1 has not been fully assessed:

1. Patients below 22 or above 75 years of age.
2. Patients with a Body Mass Index (BMI) above 32 kg/m2.
3. Patients with an Apnea Hypopnea Index (AHI) below 15 or over 65 events/hr.
4. Patients with Complete Concentric Collapse (CCC) at the soft palate level.

Study Design

Enrollment

229 participants

Anticipated

Interventions and Outcome Measures

Arms

Genio System 2.1

This is a single-arm study. All consented and eligible subjects will be implanted with the Genio 2.1 System.

Interventions

This is a single arm study, all consented and eligible subjects will be implanted with the Genio® System 2.1

Genio® System 2.1

Primary outcome measure

  • Change in Apnea Hypopnea Index (AHI4%) [ Time Frame: 12 months ]
  • Change in Oxyhemoglobin Desaturation Index (ODI4%) [ Time Frame: 12 months ]
  • Device related SAEs [ Time Frame: 12 months ]
  • Device-related and procedure-related SAEs [ Time Frame: 12 months ]

Central Contacts and Locations

Locations

PharmaDev Clinical Research Institute, LLC

Recruiting

Miami, Florida, United States, 33176

Contacts

More Information

Sponsor

Nyxoah Inc.

Last update posted

Jun 22, 2026

Last verified

Jun, 2026

Keywords

  • OSA
  • Hypoglossal Nerve Stimulation
  • Genio
  • obstructive sleep apnea

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Nyxoah Inc. on 2026-06-22.